Book a FREE consultation  
For a free consultation or assistance, please call 020 7730 6666

Browse by Category

JAK Inhibitor Alopecia Areata Treatment Development Deal Announced

It has just been announced that Rigel Pharmaceuticals, Inc. and Aclaris Therapeutics International Limited (ATIL), a wholly owned subsidiary of Aclaris Therapeutics, Inc., have come together to develop and bring to market a new treatment for Alopecia Areata based on specified Rigel JAK inhibitors in an exclusive, worldwide license agreement.

Rigel Have Partnered with Aclaris Therapeutics to Develop JAK Inhibitor Based Treatment for Alopecia AreataHope for severe alopecia areata

Under the terms of this agreement, ATIL will be responsible for continuing to develop specified Rigel JAK inhibitor compounds in order to safely and effectively treat the autoimmune condition. The companies’ press release advises this treatment will also be applied to other dermatological conditions.

It was recently discovered that Alopecia Areata – including its two rarer, more severe forms, Alopecia Totalis and Alopecia Universalis – is the second most common cause of hair loss in the world. Therefore, with this in mind, the figures given in connection with the deal are perhaps unsurprising based upon the huge numbers of people affected any potential treatment may help.

In addition to a one-off, upfront payment of $8 million, Rigel is eligible to receive ‘milestone payments’ and ‘tiered royalties’ on any future sales of the compounds developed. The milestone payments reportedly range up to $90 million depending on hitting various global development and other indication targets.

This partnership allows us to advance an opportunity that is outside of Rigel’s area of focus,” said president and CEO of Rigel, Raul R. Rodriguez. “We are delighted to partner with Aclaris to strive to bring hope to alopecia areata patients.

Circ The Belgravia Centre Hair Loss Treatment for Alopecia AreataThe Belgravia Centre

The Belgravia Centre is the leader in hair loss treatment in the UK, with two clinics based in Central London. If you are worried about hair loss you can arrange a free consultation with a hair loss expert or complete our Online Consultation Form from anywhere in the UK or the rest of the world. View our Hair Loss Success Stories, which are the largest collection of such success stories in the world and demonstrate the levels of success that so many of Belgravia’s patients achieve. You can also phone 020 7730 6666 any time for our hair loss helpline or to arrange a free consultation.

Related Stories


11th September, 2015 at 3:42 am


I stay in India and I want to come to London for the treatment can u suggest me the procedure

11th September, 2015 at 11:45 am

Sarah Belgravia

Hello Shashwat,

This treatment has not yet been developed - the companies have just announced their deal to start developing a JAK inhibitor treatment for Alopecia Areata. We do offer minoxidil-based treatment for Alopecia Areata but this cannot be sent out to India. so although you could see one of our hair loss specialists and collect your first round of treatment while you were in London, we would not be able to send you further products. Because of this, it may be best if you contact a local clinic or dermatologist and explore treatment options in your area.

30th October, 2015 at 1:44 am


Hello Sarah, Do we know if this treatment will be topical or oral? Do we know an approximate date/year this treatment will be available? Are there any JAK trials being offered by Belgravia or in London? Thanks

30th October, 2015 at 10:39 am

Sarah Belgravia

Hi Jason,

Belgravia isn't involved in these clinical trials - they are taking place at Columbia University and Yale University in the States - but from the information they have released, we understand they are exploring both topical and oral administrations of JAK inhibitors. So far it appears the topical applications have shown to be more effective in trials to date.

Development is on-going and this can take several years due to the number of tests required to ensure any drugs meet safety and efficacy criteria. We hope to have further news early next year when new trial information is due to become available and hopefully this will give a better indication as to a likely timeline for any successful treatments to be made available to Alopecia Areata patients. We will report on this as soon as we receive the latest findings or have any other updates.

Comment on this article

* required field

Will not be published

Online Consultation

Submit an instant online consultation so that one of Belgravia’s hair loss specialists can diagnose your condition and recommend an effective course of treatment, wherever you live.